ArticleDrugs & therapy perspectives : for rational drug selection and use2018
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA.
Article in Drugs & therapy perspectives : for rational drug selection and use, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.Calcified tissue international · 2021Trial
- A case and review of fibroblast growth factor-23-mediated hypophosphatemic osteomalacia in the absence of pathogenicJBMR plus · 2025Article
- Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection during Burosumab Therapy.Internal medicine (Tokyo, Japan) · 2025Article
- Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab.Archives of osteoporosis · 2025Article
- Factors associated with impaired physical functionality in X-linked hypophosphatemia.JBMR plus · 2025Article
- Phosphaturic mesenchymal tumor withTherapeutic advances in medical oncology · 2024Article
- Diagnostic and New Therapeutic Approaches to Two Challenging Pediatric Metabolic Bone Disorders: Hypophosphatasia and X-linked Hypophosphatemic Rickets.Current pediatric reviews · 2024Review
- X-Linked Hypophosphatemia: Does Targeted Therapy Modify Dental Impairment?Journal of clinical medicine · 2023Review
- Raised FGF23 Correlates to Increased Mortality in Critical Illness, Independent of Vitamin D.Biology · 2023Article
- New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.Archives of endocrinology and metabolism · 2022Review
- Nationwide Turkish Cohort Study of Hypophosphatemic RicketsJournal of clinical research in pediatric endocrinology · 2020Article
- Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia.Frontiers in pediatrics · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burosumab (Crysvita
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.